Moderna
-
Moderna wins European Commission joint procurement deal for mRESVIA RSV vaccine
The EC signed the framework agreement after a request from six participating countries, including Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal.
-
Moderna launches in Vivo CAR-T mRNA therapy mRNA-6007 for autoimmune diseases
The announcement came during Moderna’s Science Day, where the biotechnology company outlined plans to broaden its pipeline across oncology, rare diseases, and immune-mediated disorders.
-
CEPI pledges US$60M to fast-track Bundibugyo Ebola vaccines from Moderna, Oxford, and IAVI
The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).
-
Sanofi’s Nuvaxovid exhibits 50% fewer severe side effects than Moderna’s mRNA booster
Less than 10% of participants in the Nuvaxovid group experienced severe side effects that interfered with daily activities compared with 20% in the mNexspike group.
-
Moderna’s combination Covid-Flu vaccine clears key European regulatory hurdle
The EMA will now proceed with a final decision, potentially clearing the way for global distribution of this combination immunization.
-
Moderna signs five-year agreement with Mexico to boost vaccine production
The partnership forms a cornerstone of “Plan Mexico,” a government-led economic growth strategy designed to attract investment and develop domestic manufacturing capabilities.
-
Moderna invests USD140M to expand US manufacturing capabilities at Massachusetts facility
Construction at the MTC is currently underway and is scheduled for completion during the first half of 2027.
-
Moderna axes three clinical-stage mRNA candidates to focus R&D on oncology
A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.